Chugai Pharmaceutical's own in-house development pipeline has one of the strongest line-ups in Japan. By adding Roche and Genentech products based on license agreements with those companies, Chugai Pharmaceutical has benefited from a development synergy effect and assembled a top-class, innovative domestic development pipeline.
Co-Development and Joint Promotion with Roche
By concluding co-development/joint promotion agreements with Roche, Chugai Pharmaceutical has established a business model that enables it to develop and market its own products overseas as well as in Japan, and enables it to utilise Roche's global network. As a result of coordination of co-development with Roche in Europe and the United States, Chugai Pharmaceutical's development is proceeding more effectively and efficiently. Furthermore, Chugai Pharmaceutical's products can now be sold through Roche's overseas sales network, so the alliance can be expected increase sales.
- Development Synergy Effect
- This refers to the synergistic effect that enables each pharmaceutical company to save large amounts of money and time in the new-drug development process by sharing know-how, R&D results, and data from research in progress.
- Development Pipeline
- The set of products currently under development at a pharmaceutical company, from the initial development stage of each drug until the start of sales, is called the "development pipeline". The terms "product pipeline" and "new-drug pipeline" are also used.